CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 Side Effects: What the Research Reports

Real Peptides Research TeamEditorial

Updated March 3, 202610 min read

43 WORDS

Short answer

Most discussions of CJC-1295 side effects treat the compound as a single molecule. It isn't. Two pharmacokinetically distinct versions circulate under the same name, and the adverse signals described in the published literature track almost entirely with which one a study actually used.

Key takeaways

CJC-1295 is not an FDA-approved drug, has no established human safety profile, and is supplied by Real Peptides for laboratory research only.
The most cited human data comes from a 2006 Journal of Clinical Endocrinology and Metabolism report describing sustained growth hormone and IGF-1 elevation, with adverse events characterised as mild and transient.
The DAC linker binds albumin and extends terminal half-life from minutes to days, which is the single variable that separates two very different risk profiles sharing one name.
No published sex-stratified adverse-event data exists, so claims about distinct CJC-1295 side effects in men versus women are extrapolation, not evidence.
Cardiac and blood pressure concerns derive from acromegaly literature on chronic growth hormone excess, not from measured findings in studies of this compound.
The literature does not describe hair loss as an adverse effect of GHRH analogs, and no plausible follicular mechanism has been proposed.
Long-term human safety data for this compound does not exist in the published record and cannot be inferred from weeks-long trials.

Our team supplies research-grade peptides to laboratories, and the question researchers ask us most about this compound isn't potency. It's what the safety record genuinely says, and where it goes silent.

Is CJC-1295 safe?

CJC-1295 is not an FDA-approved drug and has no established human safety profile. Published CJC-1295 side effects from short clinical research include local injection site reactions, transient flushing and headache, all described as mild. No long-term human data exists. It is research-use-only material and should be handled as such.

The common oversimplification is treating an absence of reported events as evidence of safety. A few dozen healthy volunteers observed for weeks cannot surface low-frequency or slow-developing harms, which is precisely the category most growth hormone axis concerns fall into. This article covers what the human trials reported, why the DAC linker changes the entire risk picture, and what the literature says about sex differences, cardiovascular questions, hair loss and the oral route.

What the published human research actually reports

The human evidence base for this compound is small, short, and roughly two decades old. The most frequently cited clinical report, published in the Journal of Clinical Endocrinology and Metabolism in 2006 by Teichman and colleagues, described sustained elevations in growth hormone and insulin-like growth factor 1 (IGF-1) in healthy adults after administration of the long-acting analog, with a terminal half-life measured in days rather than minutes (PubMed). Adverse events in that report were characterised as generally mild and transient, with local injection site reactions and transient flushing among those described.

That is close to the full extent of controlled human CJC-1295 side effects data. Studies of that size and duration cannot detect rare events, and they say nothing about anything that takes months or years to appear.

Where the literature does get specific is at the class level. Tesamorelin, a growth hormone releasing hormone (GHRH) analog approved for HIV-associated lipodystrophy, carries prescribing information listing arthralgia, peripheral edema, myalgia, paresthesia, injection site erythema and glucose intolerance. Because CJC-1295 acts on the same GHRH receptor pathway, the tesamorelin label is the most defensible proxy available for what a sustained GHRH stimulus does in a human body.

Our team has worked with researchers designing GHRH-analog studies for years, and the pattern holds every time: the class-level signals are well characterised, the compound-specific ones are not. This article is educational. CJC-1295 is not approved for human or veterinary use and is supplied strictly for laboratory research.

Why the DAC linker changes the entire safety question

CJC-1295 exists in two forms and they are not interchangeable. The original molecule carries a Drug Affinity Complex (DAC), a maleimidopropionyl group that binds covalently to circulating albumin and stretches the terminal half-life from minutes into days. Remove the DAC and what remains is the tetrasubstituted GRF(1-29) backbone, more accurately named Mod GRF (1-29), whose reported half-life sits in the range of tens of minutes.

That single structural difference is the most important variable in any discussion of CJC-1295 side effects. Endogenous growth hormone is released in pulses, and hepatic IGF-1 production responds to pulse amplitude rather than to a flat circulating average. An albumin-bound analog holds the GHRH receptor under near-continuous stimulation, which the literature describes as a sustained bleed of growth hormone and a chronically raised IGF-1 baseline. The short-acting form produces a pulse and then clears.

Here's the part most safety write-ups miss entirely. They pool anecdotal reports from both molecules into one list, despite an exposure-duration difference of roughly two orders of magnitude. Edema, joint discomfort and impaired glucose handling are the signals associated with sustained growth hormone elevation in the endocrine literature, not with transient pulses. Attributing them to a short half-life GRF analog without naming which molecule was studied is a category error, and it is everywhere online.

For researchers procuring the short-acting form, CJC-1295 No DAC is supplied by Real Peptides with a publicly verifiable certificate of analysis confirming sequence identity and purity. That document is the only reliable way to know which molecule is in the vial.

Sex differences, cardiovascular questions, and the hair loss myth

Searches for CJC-1295 side effects in men and in women both assume sex-stratified safety data exists. It does not. The published trials were far too small to report adverse events broken out by sex. What endocrinology does establish is that growth hormone secretion is sexually dimorphic: women secrete GH in a more continuous pattern, and estrogen attenuates hepatic IGF-1 generation, so an identical GHRH stimulus can produce a smaller IGF-1 rise in women than in men. Any sex difference in response is a pharmacodynamic expectation, not a documented adverse-event pattern.

On CJC-1295 side effects and the heart, there is no published cardiac outcome data for this compound at all. The concern is inherited from acromegaly research, where chronic growth hormone and IGF-1 excess is associated with left ventricular hypertrophy, diastolic dysfunction and hypertension. Growth hormone also promotes renal sodium retention, which is the proposed mechanism behind the fluid retention and blood pressure questions researchers raise. Those are mechanistic inferences drawn from a disease state, not measured findings from studies of this analog.

Hair loss is the clearest example of a claim with nothing behind it. No published research describes alopecia as an adverse effect of GHRH analogs, and there is no known pathway by which GHRH receptor stimulation would increase androgen conversion within the follicle. We've reviewed this question repeatedly for researchers and the answer hasn't shifted: the literature does not specify a hair-loss signal for this compound in either direction.

CJC-1295 side effects: how reported signals compare by form

Placing both CJC-1295 forms alongside related GHRH analogs shows exactly where evidence exists and where it is simply absent. Regulatory status matters as much as the signal column, because approval status determines whether adverse events are systematically collected in the first place.

Compound or form	Exposure profile	Signals described in the literature	Regulatory status	Professional assessment
CJC-1295 with DAC	Albumin-bound; terminal half-life reported in days	Mild transient injection site reactions and flushing in short human research; class-level concerns centre on sustained IGF-1 elevation	Not an approved drug anywhere; prohibited in sport under the peptide hormones category	The form that carries the most theoretical risk, because continuous receptor stimulation replaces natural pulsatility
CJC-1295 without DAC (Mod GRF 1-29)	Short-acting; reported half-life in tens of minutes	Reports overwhelmingly local and transient; no sustained IGF-1 elevation described	Not an approved drug; research use only	Pharmacologically closer to endogenous GHRH signalling; most online adverse-event lists attributed to it were generated from the DAC form
Tesamorelin	Approved GHRH analog with an established label	Arthralgia, peripheral edema, myalgia, paresthesia, injection site erythema, glucose intolerance	FDA-approved for HIV-associated lipodystrophy	The only GHRH analog with systematically collected adverse-event data; the best available proxy for class effects
Sermorelin (GRF 1-29)	Short-acting native fragment	Injection site reactions, flushing and headache described historically	Previously marketed as an approved product, later discontinued commercially	Long clinical familiarity, minimal sustained IGF-1 exposure, useful comparator in study design
Endogenous GHRH	Pulsatile, cleared within minutes by DPP-4	None; physiological reference state	Not applicable	The baseline every analog is measured against, and the reason pulsatility matters more than peak concentration

What If: CJC-1295 Research Scenarios

What if a protocol calls for oral administration?

Verify oral bioavailability before anything else, because for a 30-residue peptide it is effectively negligible. Questions about adverse effects from oral CJC-1295 assume an oral route appears somewhere in the published record. It does not. Gastric pepsin and intestinal proteases cleave peptide bonds before absorption occurs, and molecules of this molecular weight cross intestinal epithelium poorly without a permeation enhancer. Any oral-route safety profile would need to be established from zero, since systemic exposure, and therefore the entire adverse-event question, changes completely when almost none of the compound reaches circulation intact.

What if a study design depends on long-term exposure data?

Build the protocol on the assumption that the data must be generated, not cited. The longest published human exposure to this analog is measured in weeks. Long-term questions are currently answerable only by extrapolation from acromegaly and growth hormone replacement literature, where sustained IGF-1 elevation has been studied across years in different populations with different baseline physiology. Any source claiming that long-term safety of CJC-1295 is established is citing something that has not been published. Treating the gap as a known unknown is the defensible position.

What if two vials labelled CJC-1295 behave differently in the same assay?

Check first whether one is the DAC form and the other is not, because that alone explains most divergent results. If both are the same form, move to the certificate of analysis: sequence confirmation, purity by HPLC, molecular mass by mass spectrometry, and CAS identity. Peptide acetate content and residual solvent variation between batches are ordinary sources of assay drift and are visible on a proper certificate. Material supplied without batch-specific documentation makes this diagnosis impossible, which is why verification precedes procurement rather than following it.

What if a supplier cannot say which form they are shipping?

Treat that as a disqualifying answer. The DAC and no-DAC molecules differ in structure, molecular weight and pharmacokinetics by a wide margin, and a supplier holding real analytical documentation can answer the question in seconds. Our team has seen material marketed simply as CJC-1295 that was, on inspection of the sequence, Mod GRF (1-29). Neither is wrong to supply. Mislabelling one as the other invalidates the comparison every downstream result depends on, and no amount of purity testing recovers a misidentified molecule.

The honest state of the evidence

Let's be direct about this: nobody can tell you CJC-1295 is safe, and anyone who states it flatly is selling something. The compound never completed the clinical program that would answer the question. The short human research that exists reports mild, transient CJC-1295 side effects, but a few dozen subjects observed over weeks is not a safety profile. It is an absence of detected harm in a sample too small to detect much of anything. Regulators have raised concerns about immunogenicity and insufficient safety characterisation across several research peptides. Not proven harmful. Not proven safe. Unestablished.

Researchers comparing compounds across the GHRH class can review the broader CJC-1295 research overview, verify batch documentation through our published certificates of analysis, and browse adjacent categories including hair and skin research compounds, oral research compounds and the wider research peptide catalog. Every compound Real Peptides supplies is for laboratory research use only.

The search for CJC-1295 side effects usually begins with someone hoping for a clean list of risks to weigh against a clean list of benefits. The literature doesn't offer that trade. What it offers instead is a well-characterised class mechanism, a handful of short human observations, and a long silence where multi-year data should sit. In research, that silence is itself information. It tells you which questions your own protocol has to answer, rather than which ones you get to assume somebody else already settled.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

CJC-1295 has no established human safety profile and is not an FDA-approved drug. Short published research described mild, transient effects such as injection site reactions and flushing, but those studies were small and brief. No long-term data exists. It is supplied strictly as a research-use-only compound for laboratory work.

The published human research describes local injection site reactions, transient flushing and headache, all characterised as mild and short-lived. Class-level concerns for GHRH analogs, drawn largely from the tesamorelin label, include arthralgia, peripheral edema, myalgia, paresthesia and glucose intolerance. These are class observations, not confirmed findings for this specific compound.

No published study reports adverse events for this compound stratified by sex, because the trials were too small. Endocrinology does show that growth hormone secretion is sexually dimorphic and that estrogen attenuates hepatic IGF-1 generation, so response magnitude can differ. That is a pharmacodynamic expectation, not documented evidence of different adverse effects.

The published literature does not describe alopecia as an adverse effect of CJC-1295 or any other GHRH analog. There is no proposed mechanism linking GHRH receptor stimulation to increased androgen conversion in hair follicles. Claims circulating online about hair loss are not supported by, nor contradicted by, any research that has actually been published.

There is no published cardiac outcome data for CJC-1295. The concern comes from acromegaly research, where chronic growth hormone and IGF-1 excess is associated with left ventricular hypertrophy, diastolic dysfunction and hypertension. Growth hormone also promotes renal sodium retention, which is the mechanism behind fluid retention and blood pressure questions. These remain inferences from a disease state.

Long-term CJC-1295 side effects have not been studied in humans. The longest published exposure is measured in weeks, so anything beyond that horizon is extrapolation from growth hormone excess literature rather than direct evidence. Sustained IGF-1 elevation is the theoretical concern, since it is the shared feature between continuous GHRH stimulation and pathological growth hormone states.

Published human research on this compound used parenteral administration, not oral, so no oral safety data exists. Oral bioavailability for a peptide of this size is effectively negligible because gastric and intestinal proteases cleave peptide bonds before absorption and large molecules cross intestinal epithelium poorly. Without systemic exposure, an oral adverse-event profile cannot be meaningfully described.

Tesamorelin is the only GHRH analog in this group with systematically collected adverse-event data, since it holds an FDA approval and carries a full label. Sermorelin, the native GRF(1-29) fragment, was historically associated with injection site reactions, flushing and headache. CJC-1295 with DAC differs from both by producing sustained rather than pulsatile stimulation.

The DAC, or Drug Affinity Complex, is a maleimidopropionyl group that binds covalently to circulating albumin and extends terminal half-life from minutes into days. Without it, the compound is the tetrasubstituted GRF(1-29) backbone properly called Mod GRF (1-29), with a half-life in the range of tens of minutes. They are pharmacokinetically different molecules.

CJC-1295 can be supplied legally for laboratory research use only and is not approved as a drug for human or veterinary use. Pricing varies widely by quantity, purity specification and whether batch-specific analytical documentation is included. Material sold without a verifiable certificate of analysis is generally cheaper for exactly that reason.

No. Real Peptides supplies research-use-only compounds and does not provide dosing, administration or preparation guidance to anyone. What we do provide is analytical documentation: sequence confirmation, purity by HPLC, molecular mass verification and CAS identity, so researchers can confirm exactly which molecule and what quantity a vial contains before designing their own protocol.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA